Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that the company's CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.
BTIG, a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services, recently initiated analyst coverage of Innate Pharma.
The Fireside chat will be held on Wednesday July 30 at 2pm EST, with 1x1 meetings hosted the same day.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
By Karen Roman ReAlta Life Sciences, Inc. said it designated Ellen Lubman as Chief Business Officer to supervise business development, capital formation and corporate strategy. Ms. Lubman has nearly 25 years of experience across small to large-cap private and public biopharmaceutical companies with a track record in strategic, transactional, and operational roles, the company stated. She previously served as Chief Business Officer at Werewolf Therapeutics, Inc. (Nasdaq: HOWL), taking the company through multiple financings including an IPO, it said. 'Ellen is a highly respected executive with a strong track record of building partnerships, raising capital, and developing successful corporate strategies for biotech and pharmaceutical companies,' said David Marek, ReAlta's CEO. 'We are excited to welcome Ellen at such a pivotal moment for our business with all three clinical programs reading out this year.' Ms. Lubman holds an M.B.A. from Stanford Graduate School of Business and a B.A. in Biology from Rutgers College. READ MORE ReAlta Drug Shows Promise in Protecting Newborn Brains from Oxygen Deprivation Injuries Never Miss our Weekly Highlights Contact: Exec Edge Editor@ Click to follow us on LinkedIn Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
EFG Companies: Top Five Questions We Hear From Dealers Reflect State of the Industry
Challenging Times Demand Sound Counsel During Second Half of 2025 DALLAS, July 29, 2025--(BUSINESS WIRE)--EFG Companies has the ear of over 1,600 retail automotive and powersports dealers and hears the impacts of the current market and economic conditions. Success in the second half of 2025 will require a mixture of strategy, innovation, and preparation to combat the challenging forces disrupting sales and revenue generation. Here are the Top Five Questions we hear from dealer principals daily – and the experienced counsel we share with them. For more information, visit Top Five Questions from Dealers What business changes should we make now, given the uncertain economy? Now is not the time to hunker down. While dealers cannot control market forces such as interest rates, tariffs, supply chain, and increasing inventory constraints, dealership owners can closely evaluate annual reinsurance and revenue generation goals. Dealers should consciously and comprehensively analyze personal wealth creation and profit metrics to ensure strong positions. Our Wealth Builder Profit Participation portfolio and Business Development Assessment process are proven tools for success. How can we mitigate losses from tariffs? A strategic focus on training and recruiting is a powerful weapon to fight the impacts of tariffs. Front-end margins and unit sales are anemic – the opportunity for dealers to shore up their business is through backend gross. To drive increased PRU and penetration, there is a need to modify behaviors that set in during COVID when front-end gross was at record highs. For training to deliver sustainable performance results, there must be a commitment from dealership management to support the processes learned in training and not revert to bad (perhaps more comfortable) habits. Ensuring pay plans are structured to motivate the desired behaviors is also key. How can we drive more traffic to our dealership? Consumer concerns about the economy, employment, and rising inflation will continue to impact dealer sales for the foreseeable future. Edmunds' research shows auto finance metrics have reached record highs. Increasing traffic and online to on-lot sales requires dealers to refocus their people on the fundamentals. Traffic-driving and retention products, such as WALKAWAY® and Drive Forever Worry Free from EFG, give consumers confidence in making a large purchase during challenging times, while increasing buyer loyalty and fixed operations revenue. The questions you should ask are 4-fold: Is it good for your brand? Is it good for the consumer? Is it good for your employees? And does it drive profit? What changes should we make to our processes? Artificial intelligence tools are all the buzz, driven by consumers' growing online purchase habits, says Cox Automotive research. Dealers who focus on value-driven differentiation will overstep the competition. Delivering a "Why Buy Here" message at every customer interaction is key. Training across all divisions to reinforce customer interaction while delivering the right products for each individual customer must be an ingrained process. How can we increase our margins and make more per sale? When front-end margins shrink, backend margins must increase. Culture, behavior, and performance are key drivers that impact results. Dealers set the tone here and must go beyond traditional training methodologies to focus on needs-based selling that delivers results. Our data show that properly trained team members can generate an incremental $206,400 average annual F&I profit per producer per year. "If we take the lessons learned from COVID and the Great Recession, we know the root cause issues impacting dealer profit," said Jennifer Rappaport, CEO of EFG Companies. "Some of today's challenges may be unique, but the underlying strategy is the same. With nearly 50 years of empirical data on training and consumer protection products, we intimately understand the challenges facing automotive and powersports dealers. Our dedication to a results-focused client engagement model that combines F&I products with a model-agnostic reinsurance portfolio has delivered proven results. We feel confident that our counsel will once again ensure our customers successfully weather these challenges." About EFG CompaniesFor nearly 50 years, EFG Companies has provided consumer protection programs for vehicles and residences across seven market channels. The company's strategic intent is to build sustainable market differentiation and profitability for its clients and partners, including dealers, lenders, manufacturers, independent marketers, and agents. EFG's award-winning engagement model is built upon the belief that the company serves as an extension of its clients' management teams, providing ongoing F&I development, training, product development, compliance, and nationally recognized product administration with an ASE-certified claims team. Learn more about EFG at: View source version on Contacts Marcia Barnettmbarnett@ 214-868-8861 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a minute ago
- Yahoo
SoFi Technologies (SOFI) Stock Climbs On Strong Q2 Results, Raises Guidance
July 29 - SoFi Technologies (NASDAQ:SOFI) rose about 5% in premarket trading on Tuesday after beating the Q2 estimate and reporting higher revenue and earnings for the second quarter of 2025. Warning! GuruFocus has detected 7 Warning Sign with SOFI. The company posted net revenue of $854.9 million for the quarter ended June 30, up 43% from $598.6 million a year earlier. Adjusted net revenue reached $858.2 million, a 44% increase from the same period last year. Net income came in at $97.3 million, up from $17.4 million. Adjusted earnings before interest, taxes, depreciation and amortization increased 81% to $249.1 million. Fee-based revenue advanced 72% to $377.5 million as SoFi's loan platform and other services contributed more to results. Membership rose 34% year over year to 11.7 million, while total products on the platform grew to 17.1 million. Loan originations totaled $8.8 billion for the quarter, including gains in personal, student and home loans. The company said it raised full-year guidance, pointing to growth in products and demand for its technology platform. Based on the one year price targets offered by 16 analysts, the average target price for SoFi Technologies Inc is $16.63 with a high estimate of $27.00 and a low estimate of $6.00. The average target implies a downside of -20.90% from the current price of $21.02. Based on GuruFocus estimates, the estimated GF Value for SoFi Technologies Inc in one year is $11.50, suggesting a downside of -45.29% from the current price of $21.02. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
